{"disease":{"id":"locally-advanced-cscc-lacscc","name":"locally advanced cscc lacscc"},"drugs":{"marketed":[{"drug_id":"cosibelimab","indication_name":"locally advanced CSCC (laCSCC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Unloxcyt","generic_name":"COSIBELIMAB","company_name":"Checkpoint Therapeutics Inc","drug_phase":"marketed","molecular_target":"Pd-1","drug_class":"Programmed Death Ligand-1 Blocker [EPC]","quality_score":10,"revenue":null,"mechanism":"Unloxcyt blocks the PD-1/PD-L1 pathway to help the immune system recognize and attack cancer cells."}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[],"total":0},"guidelines":[],"source":"Drug Landscape verified database"}